NCT03317899 · OUTCOME

Median Number of Documented Infections Treatment During the Auto HSCT Inpatient Stay

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: documented inpatient stay infections
Interval / dispersion: Full Range
Time frame: Up to 60 days

What was measured

Will be defined as a positive blood culture not ultimately deemed to be due to a contaminant

Groups in this outcome

Group I (auto HSCT tbo-filgrastim)

Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies

Group II (auto HSCT)

Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Group I (auto HSCT tbo-filgrastim)	38
Group II (auto HSCT)	39

Reported measurements

Source class 1

Values in documented inpatient stay infections · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Group I (auto HSCT tbo-filgrastim)	0	Not reported	0	3	Not reported
Group II (auto HSCT)	0	Not reported	0	2	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

group Ids
OG000
OG001
non Inferiority Type
OTHER
p Value
0.936
statistical Method
Wilcoxon (Mann-Whitney)

Complete source fields

analyses

group Ids
OG000
OG001
non Inferiority Type
OTHER
p Value
0.936
statistical Method
Wilcoxon (Mann-Whitney)

classes

categories
measurements
group Id
OG000
lower Limit
0
upper Limit
3
value
0
group Id
OG001
lower Limit
0
upper Limit
2
value
0

denoms

counts
group Id
OG000
value
38
group Id
OG001
value
39
units
Participants

description

Will be defined as a positive blood culture not ultimately deemed to be due to a contaminant

dispersion Type

Full Range

groups

description
Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies
id
OG000
title
Group I (auto HSCT tbo-filgrastim)
description
Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies
id
OG001
title
Group II (auto HSCT)

param Type

MEDIAN

reporting Status

POSTED

time Frame

Up to 60 days

title

Median Number of Documented Infections Treatment During the Auto HSCT Inpatient Stay

type

SECONDARY

unit Of Measure

documented inpatient stay infections

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice